27514242|t|Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism
27514242|a|Parkinson's disease (PD) and other parkinsonian syndromes are chronic, progressive neurodegenerative diseases. With advancing disease, both motor and non-motor symptoms represent a considerable burden and symptom relief and quality of life improvement become the main goal of treatment. Botulinum toxins (BTX) are an effective treatment modality for many neurological conditions. To understand the potential usefulness of BTX in this population, we performed a retrospective chart review of all patients with a clinical diagnosis of idiopathic PD and atypical parkinsonism who received treatment with BTX injections in our center from 1995 to 2014 for a variety of symptoms. Response to BTX was assessed using a subjective Clinical Global Impression. Records of 160 patients were reviewed. Probable idiopathic PD was the diagnosis in 117 patients (73.1%). The main indication for BTX treatment was pain (50.6% of cases). Other indications were the treatment of functional impairment resulting from dystonia (26.25%), sialorrhea (18.75%), freezing of gait, and camptocormia. Considering pain as indication, 81% of all patients with PD reported benefits after the first BTX injections. This benefit was maintained after the last recorded visit without significant difference in outcome compared with the first injection (p=0.067). Similar results were observed in patients with atypical parkinsonism. Our results confirm the safety and efficacy of different uses of BTX in the symptomatic treatment of patients with parkinsonism even in advanced stages of the disease, and suggest BTX treatment could have a safe and useful role in the treatment of pain in this population.
27514242	0	15	Botulinum Toxin	T116,T121,T131	C0006055
27514242	23	38	Refractory Pain	T184	C0030200
27514242	49	57	Symptoms	T184	C1457887
27514242	61	73	Parkinsonism	T047	C0242422
27514242	74	93	Parkinson's disease	T047	C0030567
27514242	95	97	PD	T047	C0030567
27514242	109	131	parkinsonian syndromes	T047	C0242422
27514242	136	143	chronic	T079	C0205191
27514242	145	156	progressive	T169	C0205329
27514242	157	183	neurodegenerative diseases	T047	C0524851
27514242	200	207	disease	T047	C0012634
27514242	214	219	motor	T184	C0426980
27514242	224	242	non-motor symptoms	T184	C1457887
27514242	268	274	burden	T078	C2828008
27514242	279	286	symptom	T184	C1457887
27514242	287	293	relief	T033	C0564405
27514242	298	313	quality of life	T078	C0034380
27514242	314	325	improvement	T077	C2986411
27514242	342	346	goal	T170	C0018017
27514242	350	359	treatment	T061	C0087111
27514242	361	377	Botulinum toxins	T116,T121,T131	C0006055
27514242	379	382	BTX	T116,T121,T131	C0006055
27514242	391	400	effective	T080	C1704419
27514242	401	410	treatment	T061	C0087111
27514242	411	419	modality	T078	C0695347
27514242	429	452	neurological conditions	T047	C0027765
27514242	472	481	potential	T080	C3245505
27514242	482	492	usefulness	T080	C3827682
27514242	496	499	BTX	T116,T121,T131	C0006055
27514242	508	518	population	T098	C1257890
27514242	523	532	performed	T169	C0884358
27514242	535	548	retrospective	T080	C1514923
27514242	549	561	chart review	T058	C0541653
27514242	569	577	patients	T101	C0030705
27514242	585	603	clinical diagnosis	T060	C0332140
27514242	607	620	idiopathic PD	T047	C0865475
27514242	625	646	atypical parkinsonism	T047	C4302185
27514242	660	669	treatment	T169	C0039798
27514242	675	689	BTX injections	T061	C1321035
27514242	697	703	center	T093	C1708333
27514242	739	747	symptoms	T184	C1457887
27514242	749	757	Response	T032	C0871261
27514242	761	764	BTX	T116,T121,T131	C0006055
27514242	769	777	assessed	T052	C1516048
27514242	786	823	subjective Clinical Global Impression	T170	C3639708
27514242	825	832	Records	T170	C0034869
27514242	840	848	patients	T101	C0030705
27514242	854	862	reviewed	T080	C1709940
27514242	873	886	idiopathic PD	T047	C0865475
27514242	895	904	diagnosis	T033	C0011900
27514242	912	920	patients	T101	C0030705
27514242	939	949	indication	T078	C3146298
27514242	954	957	BTX	T116,T121,T131	C0006055
27514242	958	967	treatment	T061	C0087111
27514242	972	976	pain	T184	C0030193
27514242	1001	1012	indications	T078	C3146298
27514242	1022	1031	treatment	T061	C0087111
27514242	1035	1056	functional impairment	T033	C4062321
27514242	1057	1066	resulting	T169	C0678226
27514242	1072	1080	dystonia	T184	C0013421
27514242	1091	1101	sialorrhea	T047	C0037036
27514242	1112	1128	freezing of gait	T184	C0860515
27514242	1134	1146	camptocormia	T020	C0264162
27514242	1160	1164	pain	T184	C0030193
27514242	1168	1178	indication	T078	C3146298
27514242	1191	1199	patients	T101	C0030705
27514242	1205	1207	PD	T047	C0030567
27514242	1208	1216	reported	T058	C0700287
27514242	1217	1225	benefits	T081	C0814225
27514242	1242	1256	BTX injections	T061	C1321035
27514242	1263	1270	benefit	T081	C0814225
27514242	1275	1285	maintained	T169	C1314677
27514242	1296	1315	last recorded visit	T058	C1512346
27514242	1336	1346	difference	T080	C1705242
27514242	1350	1357	outcome	T169	C1274040
27514242	1358	1366	compared	T052	C1707455
27514242	1382	1391	injection	T061	C0021485
27514242	1411	1418	results	T169	C1274040
27514242	1436	1444	patients	T101	C0030705
27514242	1450	1471	atypical parkinsonism	T047	C4302185
27514242	1477	1484	results	T169	C1274040
27514242	1508	1516	efficacy	T080	C1280519
27514242	1520	1529	different	T080	C1705242
27514242	1530	1534	uses	T169	C0457083
27514242	1538	1541	BTX	T116,T121,T131	C0006055
27514242	1549	1560	symptomatic	T169	C0231220
27514242	1561	1570	treatment	T169	C1522326
27514242	1574	1582	patients	T101	C0030705
27514242	1588	1600	parkinsonism	T047	C0242422
27514242	1609	1617	advanced	T080	C0205179
27514242	1618	1624	stages	T079	C1306673
27514242	1632	1639	disease	T047	C0012634
27514242	1645	1652	suggest	T078	C1705535
27514242	1653	1656	BTX	T116,T121,T131	C0006055
27514242	1657	1666	treatment	T061	C0087111
27514242	1696	1700	role	T077	C1705810
27514242	1708	1717	treatment	T169	C1522326
27514242	1721	1725	pain	T184	C0030193
27514242	1734	1744	population	T098	C1257890